This biopharmaceutical company has seen 2 positive estimate revisions in the last 60 days. The Zacks Consensus Estimate has also moved considerably higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if yesterday’s price climb can turn into more strength down the road.
Endocyte currently has a Zacks Rank #1 (Strong Buy) while its Earnings ESP is 0.00%.
Investors interested in the Med-Drugs industry may also consider stocks like Mallinckrodt plc (MNK), Lannett Company, Inc. (LCI) and Endo International plc (ENDP). While Mallinckrodt and Lannett Company sport a Zacks Rank #1, Endo International bears a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment